Darren Carpizo, MD, General Surgery, Rochester, NY

DarrenRCarpizoMD

General Surgery Rochester, NY

Surgical Oncology (Other than Breast)

Assistant Professor, Surgery, UMDNJ-Robert Wood Johnson Medical School

Dr. Carpizo is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Carpizo's full profile

Already have an account?

Education & Training

  • UCLA Medical Center
    UCLA Medical CenterResidency, General Surgery, 1997 - 2006
  • University of Illinois College of Medicine
    University of Illinois College of MedicineClass of 1997

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2008 - 2021
  • NY State Medical License
    NY State Medical License 2006 - 2021
  • CA State Medical License
    CA State Medical License 1999 - Present
  • American Board of Surgery Surgery

Awards, Honors, & Recognition

  • Fellow (FACS) American College of Surgeons

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Neoadjuvant Chemoradiation Improves Margin Positivity Rates After Pancreaticoduodenectomy in T1 and T2 Resectable Pancreatic Cancer: An Analysis of the National Cancer...  
    Mihir M Shah, Darren R Carpizo, Miral S Grandhi, Russell C Langan, Journal of The American College of Surgeons

Authored Content

  • Neoadjuvant Chemoradiation Improves Margin Positivity Rates After Pancreaticoduodenectomy in T1 and T2 Resectable Pancreatic Cancer: An Analysis of the National Cancer DatabaseOctober 2018

Press Mentions

  • $500K Grant Aids Exploration of Genetic Changes in Pancreatic Cancer for New Treatment Targets
    $500K Grant Aids Exploration of Genetic Changes in Pancreatic Cancer for New Treatment TargetsAugust 23rd, 2018
  • Meet Our 2018 Research Grantees: Translational Awards
    Meet Our 2018 Research Grantees: Translational AwardsJuly 18th, 2018
  • Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer
    Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal CancerJuly 11th, 2018
  • Join now to see all

Professional Memberships